Skip to content
Regulatory

FDA Peptide Timeline 2026

Last updated

The 2026 timeline of FDA action on therapeutic peptides — the April 15 reclassification, the July Pharmacy Compounding Advisory Committee meeting, the Aug 24 warning letters to five online sellers (posted Sept 1), the Aug 27 Fifth Circuit GLP-1 ruling, and the no-compounding list outlook.

Latest: Sept 1, 2026 — FDA posts five warning letters to online peptide sellers

Issued Aug 24, 2026 by CDER and posted Sept 1, the letters went to Peptide Partners LLC, Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC, and TXP Innovations LLC (Tex Peptides) over injectable semaglutide, tirzepatide, retatrutide, tesamorelin, elamipretide (SS-31), and bremelanotide (PT-141) sold as unapproved new drugs under "research use only" labels. The letters are direct-to-consumer unapproved-drug cases, not compounding cases — but they sit inside the same enforcement wave as the Category 2 / no-compounding framework. Read the buyer explainer → · News brief →

Legal update: Aug 27, 2026 — Fifth Circuit upholds FDA GLP-1 delisting

The Fifth Circuit upheld the FDA's removal of semaglutide and tirzepatide from the drug shortage list. Bulk compounding of these GLP-1s for general use is no longer allowed; patient-specific compounding for an individual with a documented medical need remains legal. Read the full ruling analysis →

April 15, 2026 — Reclassification

The FDA published a Federal Register notice removing twelve therapeutic peptides — BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, Epitalon, GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF — from Category 2 of the 503A bulk drug substances evaluation framework. The action moves these compounds to an interim evaluation tier pending final 503A Bulks List placement.

Practical effect: The removal ended the Category 2 safety-risk flag, which had operated as a de facto freeze on at-scale compounding. It did not make the twelve peptides approved, and none of them is lawfully compoundable today: the substances sit in an interim evaluation tier until FDA completes the 503A Bulks List rulemaking, and the July 2026 PCAC recommendation is advisory, not a rule.

April 15 to July 23 — Interim window

The 90-day window between reclassification and the PCAC decision is when the supply chain repositions. Compounding pharmacies are credentialing additional state non-resident registrations, hiring peptide-specific pharmacist expertise, and standing up quality protocols ahead of the post-PCAC volume surge. Telehealth brands with GLP-1 prescribing infrastructure are preparing peptide-category expansions for August/September launch.

July 23–24, 2026 — PCAC meeting

The Pharmacy Compounding Advisory Committee met at FDA's White Oak Campus (docket FDA-2025-N-6895) to consider seven peptide bulk drug substances for the 503A Bulks List — BPC-157-related substances on July 23, and Emideltide (DSIP), Epitalon, KPV, MOTS-c, Semax, and TB-500 on July 24. PCAC is an advisory panel; its recommendations are nonbinding and historically have carried weight, but FDA makes the final decision through rulemaking.

Three outcomes are possible per peptide: full approval, approval with restrictions, or referral for further study. Full breakdown of likely outcomes →

Outcome (Jul 24): PCAC recommended six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for the 503A Bulks List and did not recommend emideltide (DSIP). The vote is nonbinding and does not make any of them lawful to compound today; formal rulemaking can take up to a year. What the vote means for patients →

August 19, 2026 — Overton nomination

President Trump nominated Dr. Heidi Overton, deputy director of the White House Domestic Policy Council, to lead the FDA — his third choice for the post after acting commissioner Kyle Diamantas and former Rep. Brad Wenstrup (R-Ohio) declined. Overton has made no public statements on peptide compounding, the 503A/503B lists, or GLP-1 policy. No hearing date has been set, and Senate HELP chair Bill Cassidy has called her record "alone is almost disqualifying." The 503A bulks-list rulemaking and the undecided 503B GLP-1 exclusion both land on the next commissioner's desk — confirmed or acting. What the nomination means for peptide compounding and the 503A bulks list →

August 19, 2026 — Novo asks FDA to ban semaglutide compounding

Novo Nordisk formally asks the FDA to place semaglutide on the Demonstrable Difficulties for Compounding (DDC) lists (request first filed Oct 2024, Docket FDA-2017-N-2562), joining Eli Lilly's push to ban GLP-1 compounding while both companies' molecules remain central to the compounding-policy fight. Compounded GLP-1 ban coverage →

August 27, 2026 — Fifth Circuit upholds FDA GLP-1 delisting

In two unpublished per curiam opinions issued the same day (Case 25-10600, tirzepatide/Lilly; Case 25-10758, semaglutide/Novo), the Fifth Circuit affirmed the district courts and upheld the FDA's removal of Ozempic, Wegovy, Mounjaro, and Zepbound from the drug shortage list. The ruling ends the last legal avenue for bulk (503B) compounding of these molecules for general use; patient-specific 503A compounding for an individual with a documented medical need remains lawful. The 503B bulks-list exclusion and the DDC nomination remain pending as backstops that would keep the ban in place even in a future shortage. Full ruling analysis → · Opinion 25-10600 · Opinion 25-10758

August 24 / September 1, 2026 — Five warning letters to online sellers

CDER issued five warning letters on August 24, 2026 — to Peptide Partners LLC, Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC, and TXP Innovations LLC (dba Tex Peptides) — after reviewing each company's website in July 2026. The FDA posted all five letters on September 1, and Pharmaceutical Technology covered the wave September 2. Each letter classifies the seller's semaglutide, tirzepatide, retatrutide, tesamorelin, elamipretide (SS-31), and bremelanotide (PT-141) products — sold under "research use only" labels — as unapproved new drugs in violation of sections 301(d) and 505(a) of the FD&C Act.

These are direct-to-consumer unapproved-drug cases, not compounding cases. They matter to the compounding picture because they show the enforcement track running parallel to the 503A/503B bulks-list review: no compounding pathway authorizes an unapproved injectable sold from a web storefront, and "research use only" labeling does not defeat FDA's intended-use finding. Read the buyer explainer → · News brief →

September 2, 2026 — UCLA Health publishes a six-peptide evidence review

Evidence cluster, not an FDA action: UCLA Health's sports-medicine team published a Q&A reviewing six popular peptide supplements — BPC-157, TB-500 (thymosin beta-4), CJC-1295, MK-677 (ibutamoren), ipamorelin and GHK-Cu — alongside its scoping review in The American Journal of Sports Medicine. The verdict on all six: "cannot be recommended" for musculoskeletal recovery — no controlled human trials for most of them, thin or absent human evidence, and WADA-prohibited status for all but GHK-Cu as of the review. None of the six is FDA-approved. Read the per-peptide evidence breakdown →

September 4, 2026 — Strive Pharmacy CEO: pre-sourcing peptide ingredients ahead of the 503A Bulks List rule

Strive Pharmacy co-founder and CEO Nate Hill told Pharmaceutical Executive that his pharmacy — a major 503A/503B compounder — is already preparing for legal peptide compounding while the FDA decides whether to add peptides to the 503A Bulks List. In a Q&A published September 4, Hill said Strive is pre-sourcing active pharmaceutical ingredients and running stability, potency, and sterility testing on a limited set of higher-demand SKUs, and that it is consulting legal counsel on where the agency's decision stands. Hill was explicit that preparation is not production: "we're not going to produce them until it is moved over to category one."

The signal is preparation, not a rule change. The July 23–24 PCAC recommendation of six peptides was advisory and nonbinding — no proposed rule has been published, none of the six is on the 503A Bulks List, and none is lawfully compoundable today. The FDA has not made a final decision on compounded peptides; a proposed rule, public comment period, and final rule in the Federal Register must all be completed before any of the six can be added to the list.

Category 2 and the no-compounding list — where things stand (Sept 2026)

Category 2 is FDA's interim-policy flag for bulk drug substances that "may present significant safety risks" and get no compounding enforcement discretion. As of the agency's April 22, 2026 list, the peptides still on it are GHRP-2, GHRP-6, ipamorelin acetate (503B), and kisspeptin-10 (503A). BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon are not currently Category 2 — their nominations were withdrawn in 2026 — but withdrawal is procedural, not a green light, and none is lawfully compoundable today. The GLP-1 track is separate: the April 30 proposal would exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, and the Aug 27 Fifth Circuit ruling affirmed the delistings that ended bulk GLP-1 compounding. See the FDA Category 2 page and the peptide legality FAQ.

September 2026 onward — Rulemaking and enforcement in parallel

Following the July PCAC recommendation, FDA continues the 503A Bulks List rulemaking (docket FDA-2018-N-4845); the recommendation is advisory and formal rulemaking can take up to a year, so none of the six recommended peptides is lawfully compoundable today. In parallel, the enforcement track is active: the Aug 24 warning letters (posted Sept 1) put online sellers of unapproved injectables on notice, with a 15-business-day response window and possible escalation to seizure and injunction. Counterfeit pressure on the gray market continues to draw agency attention.

Q4 2026 — Outlook

Two tracks shape the rest of 2026. On rulemaking, FDA has not set a timeline for a proposed or final 503A Bulks List rule, so the six peptides PCAC recommended in July remain not lawfully compoundable. On enforcement, the Sept 1 warning-letter postings are public records: sellers of unapproved injectables face 15-business-day response deadlines and possible escalation to seizure and injunction, and state boards continue to set their own compounding rules on top of the federal floor.

Sources we monitor